Jubilant Life Sciences receives ANDA approvals for Irbesartan, Cetirizine Hydrochloride

25 Feb 2015 Evaluate

Jubilant Life Sciences, an integrated Pharmaceuticals and Life Sciences Company, has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Irbesartan Tablets USP, 75 mg, 150 mg, and 300 mg and Cetirizine Hydrochloride Tablets (Chewable), 5 mg and 10 mg.

Irbesartan Tablets USP, 75 mg, 150 mg, and 300 mg is the generic version of Avapro (of Sanofi-Aventis), which is used for treating hypertension and nephropathy in type II diabetic patients. The total market size for Irbesartan Tablets as per IMS is approximately $50 million per annum.

Cetirizine Hydrochloride Tablets (Chewable), 5 mg and 10 mg is the generic version of Zyrtec Chewable Tablets (of Mcneil), used as an anti-histamine for the treatment of allergies.

Jubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally, as on December 31, 2014. This includes 72 ANDAs filed in the US, of which 35 have been approved and 46 Dossier filings in Europe. The company has so far received 9 ANDA approvals during FY 2015.

Jubilant Pharmova Share Price

1076.40 7.20 (0.67%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×